Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
AVAILABLE
NCT07950202

A Protocol for the Expanded Access of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Monotherapy in Participants With Endometrial Cancer (MK-2870-060)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This trial is an expanded access program (EAP) to give participants the chance to receive sacituzumab tirumotecan (also called sac-TMT) for advanced or recurrent endometrial cancer. Sac-TMT is a trial medicine that is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. Endometrial cancer starts in the tissue inside the uterus (womb). Advanced means the cancer has spread to other parts of the body (metastatic) and cannot be removed with surgery. Recurrent means the cancer came back after treatment. To join the trial, a participant must meet all these criteria: * Surgery or radiation is not an option. * They received prior treatment with platinum-based chemotherapy and immunotherapy, separately or in combination, for their cancer. Immunotherapy is a treatment that helps the immune system fight diseases such as cancer. * There is no other good treatment choice for their cancer. Participants will receive sac-TMT until the drug is approved and available in the US or the sponsor ends the EAP. The purpose of this EAP is to provide access to sac-TMT for eligible participants with endometrial cancer.

Official title: A Multicenter, Open-label Protocol for the Expanded Access of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Monotherapy in Patients With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-060)

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-11-20

Healthy Volunteers

Not specified

Interventions

DRUG

Sacituzumab tirumotecan

Intravenous (IV) Infusion